A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

NCT05979363 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Leukemia

Interventions

BIOLOGICAL: anti-BCMA CAR-T
DRUG: VRD-based regimen

Sponsor

Institute of Hematology & Blood Diseases Hospital, China